

## **G-NEOSTIGMINE** **INJECTION** (Neostigmine Methyl sulphate BP)

### **DESCRIPTION :**

Each 1-ml contains; 0.5 mg of Neostigmine Methyl sulphate BP.

### **USES :**

G-Neostigmine injection is used for the treatment of the systemic control of Myasthenia gravis when oral therapy is impractical. The prevention and treatment of post-operative distention and urinary retention after mechanical obstruction has been excluded. Reversal of nondepolarising neuromuscular blockade for surgical anaesthetic procedures.

### **DOSAGE AND ADMINISTRATION :**

By intra-muscular or sub-cutaneous injection. Symptomatic control of myasthenia gravis; 1 ml of the 1 : 2000 solution (0.5 mg) intra-muscularly or subcutaneously. Subsequent dose should be based on the individual patient's response.

Treatment of post-operative distention; 1 ml of the 1 : 2000 solution (0.5 mg) intra-muscularly or subcutaneously or as required. Prevention of post-operative distention and urinary retention; 1 ml of the 1 : 4000 solution (0.25 mg) intra-muscularly or subcutaneously as soon as possible after operation; repeat every 4-6 hours for 2-3 days.

Treatment of urinary retention; 1 ml of the 1 : 2000 solution (0.5 mg) intra-muscularly or subcutaneously. If urination does not occur within an hour, the patient should be catheterized. After the patient has voided, or the bladder has been emptied, continue the 0.5 mg injection every 3 hrs, for at least 5 injections.

Reversal of Effects of Nondepolarizing Neuromuscular Blocking Agents; when G-Neostigmine is administered intra-venously, it is recommended that atropine sulphate (0.6-1.2 mg) also be given intravenously using separate syringe. The usual dose is 0.5 to 2 mg is given by slow intravenous injection, repeated as required. On exceptional cases total dose should be exceed 5 mg.

Neonate : 50-250 micrograms every 4 hrs.

Child : 200-500 micrograms as recommended.

### **SIDE-EFFECTS :**

Nausea, vomiting, increased salivation, diarrhoea and abdominal cramps (more marked with high doses). Signs of overdose are increased gastrointestinal discomfort, bronchial secretions and sweating, involuntary defecation and micturition, miosis, nystagmus, bradycardia, hypotension, agitation, excessive dreaming and weakness eventually leading to fasciculation and paralysis.

### **PRECAUTIONS :**

Asthma, bradycardia, recent myocardial infarction, epilepsy, hypotension, parkinsonism, vagotonia, peptic ulceration. Atropine or other antidote to muscarinic effects may be necessary (particularly when neostigmine is given by injection), but it should not be given routinely as it may mask signs of overdose.

### **CONTRA-INDICATIONS :**

G-Neostigmine is contra-indicated in-patients with known hypersensitivity to the drug. It is also contraindicated in patients with peritonitis or mechanical obstruction of the intestinal or urinary tract.

### **DRUG INTERACTIONS :**

Anti-arrhythmic : procainamide, quinidine and possible propafenone antagonise effect of neostigmine. Antibacterial; aminoglycosides, clindamycin, lincomycin and polymyxins antagonise effect of neostigmine.

### **PACKING QUANTITIES :**

G-Neostigmine : 1 ml x 5 ampoule & 10 ml multi dose vial.



Manufactured by :



**Gonoshasthaya Pharmaceuticals Ltd.**

Mirzanagar via Savar Cantt., Savar, Dhaka-1344, Bangladesh

Included in WHO  
Essential Drugs List